The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials

Background Migraine is a common neurovascular disorder that has a severe impact on the individual daily life. Atogepant (AGN-241689) is an orally ingested, small-molecule drugs belonging to calcitonin gene-related peptide receptor antagonist, which has been initiated for the prophylactic treatment o...

Full description

Saved in:
Bibliographic Details
Published in:Journal of headache and pain 2022-01, Vol.23 (1), p.19-19, Article 19
Main Authors: Tao, Xinyu, Yan, Zeya, Meng, Jiahao, Wang, Wei, Dai, Qiling, Zhou, Qiufeng, Wang, Zhifeng, Wang, Zhong
Format: Article
Language:English
Subjects:
Analgesics
Calcitonin
Calcitonin gene-related peptide
Clinical outcomes
Clinical trials
Disease prevention
Headache
Humans
Internal Medicine
Medicine
Medicine & Public Health
Migraine
Migraine Disorders - drug therapy
Migraine Disorders - prevention & control
Neurology
Pain Medicine
Patient safety
Patients
Piperidines
Placebos
Pyridines
Pyrroles
Randomized Controlled Trials as Topic
Research Article
Safety
Spiro Compounds
Systematic review
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Migraine is a common neurovascular disorder that has a severe impact on the individual daily life. Atogepant (AGN-241689) is an orally ingested, small-molecule drugs belonging to calcitonin gene-related peptide receptor antagonist, which has been initiated for the prophylactic treatment of migraine. However, there is no comprehensive literature to study the efficacy and safety of atogepant for the treatment of migraine. In this article, we present a meta-analysis of the available studies. Methods MEDLINE, Embase, Cochrane Library and ClinicalTrials.gov were searched before October 20, 2021 for any relevant literature. Eventually, three randomized clinical trials (RCTs) with 2,466 patients were included in our study. Results We pooled 2,466 patients from 3 RCTs and primary outcome was mean monthly migraine days, the secondary endpoints were monthly headache days, acute medication use days per month and ≥ 50% reduction in monthly migraine days, baseline to end of trials. It was found that atogepant (10 mg, 30 mg, 60 mg once a day) led to a significant reduction in monthly migraine days ( P  
ISSN:1129-2369
1129-2377
DOI:10.1186/s10194-022-01391-2